PI3キナーゼを標的とするがん治療

• Project/Area Number: 20015048
• Research Category: Grant-in-Aid for Scientific Research on Priority Areas
• Allocation Type: Single-year Grants
• Review Section: Biological Sciences
• Research Institution: Japanese Foundation For Cancer Research
• Principal Investigator: 矢守 隆夫 Japanese Foundation For Cancer Research, 癌化学療法センター・分子薬理部, 部長 (60200854)
• Co-Investigator(Kenkyū-buntansha): 旦 慎吾 財団法人癌研究会, 癌化学療法センター・分子薬理部, 研究員 (70332202)
• Project Period (FY): 2008 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥11,100,000 (Direct Cost: ¥11,100,000); Fiscal Year 2009: ¥5,500,000 (Direct Cost: ¥5,500,000); Fiscal Year 2008: ¥5,600,000 (Direct Cost: ¥5,600,000)
• Keywords: PI3K / 機能獲得型変異体 / がん / がん細胞パネル / 血管新生

Research Abstract

がんの増殖・生存に関わるPI3Kは、がん治療の有力な標的と考えられる。我々は、新規PI3K阻害剤ZSTK474を開発し、世界に先駆けPI3K標的がん治療の有効性を証明した。本研究では、PI3K阻害剤の臨床開発に向け以下の知見を得た。
1) PI3K遺伝子変異の解析:クラスIPI3Kの触媒サブユニットp110には4種のアイソフォーム(α、β、δ、γ)があり、各々PIK3CA、-B,-Dおよび-G遺伝子によってコードされている。PIK3CA変異のみ注目されているが、他の3種の変異は報告がない。そこで39種類のがん細胞株(JFCR39)でPIK3CB、-D,-G遺伝子の全塩基配列を決定し、ミスセンス変異を初めて同定した(PIK3CBに5箇所、PIK3CDに3箇所、PIK3CGに8箇所)。これらが機能獲得型変異かどうかは興味深い。
2) PI3K遺伝子変異を持つがんに対する効果:JFCR39におけるPI3K変異プロフィルとZSTK474に対する感受性に相関があるかどうかを細胞レベルならびに動物レベル(ゼノグラフト)で調べたが、有意な相関は認められなかった。よって、PI3K阻害剤の抗がん効果は、PI3K変異状態には無関係と考えられた。
3) PI3Kスーパーファミリー(クラスI、II、III、PI4KおよびPI3K関連キナーゼ)への効果:ZSTK474はクラスIPI3Kへの特異性が高いことが判明した。
4) 脳腫瘍への効果:脳腫瘍同所移植モデルにおいてZSTK474は経口投与で有効性を示したことから、脳腫瘍治療への応用が期待された。
5) 他の薬剤との併用効果:ヌードマウス移植ヒトゼノグラフトに対しZSTK474は、mTOR阻害剤ラバマイシンとの併用で効果増強を示した。PI3K経路を2箇所で阻害する治療は有望と考えられた。

Research Products

• [Journal Article] Correlating PI3K inhibitor efficacy with signaling pathway status : in silico and biological evaluations (2010)
  • Author(s): Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T.
  • Journal Title: Cancer Res (in press)
  • Peer Reviewed
• [Journal Article] Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations (2010)
  • Author(s): Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y.
  • Journal Title: Lung Cancer (in press)
  • Peer Reviewed
• [Journal Article] Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylene dioxyquinolin-4-one monosodium phosphate(CHM-1-P-Na)as a potent antitumor agent (2010)
  • Author(s): Chou LC, Chen CT, Lee JC, Way TD, Huang CH, Huang SM, Teng CM, Yamori T, Wu TS, Sun CM, Chien DS, Qian K, Morris-Natschke SL, Lee KH, Huang LJ, Kuo SC.
  • Journal Title: J Med Chem 53(4) Pages: 1616-26
  • Peer Reviewed
• [Journal Article] Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39 (2010)
  • Author(s): Kong D, Dan S, Yamazaki K, Yamori T.
  • Journal Title: Eur J Cancer 46(6) Pages: 1111-21
  • Peer Reviewed
• [Journal Article] Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions (2010)
  • Author(s): Momose I, Ohba S, Tatsuda D, Kawada M, Masuda T, Tsujiuchi G, Yamori T, Esumi H, Ikeda D.
  • Journal Title: Biochem Biophys Res Commun 392(3) Pages: 460-6
  • Peer Reviewed
• [Journal Article] Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS (2009)
  • Author(s): Akashi T, Yamori T.
  • Journal Title: Proteome Sci 7 Pages: 14-14
  • Peer Reviewed
• [Journal Article] Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest (2009)
  • Author(s): Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T.
  • Journal Title: Biochem Biophys Res Commun 379(1) Pages: 104-9
  • Peer Reviewed
• [Journal Article] The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models (2009)
  • Author(s): Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V.
  • Journal Title: Br J Cancer 101(2) Pages: 350-6
  • Peer Reviewed
• [Journal Article] Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor (2009)
  • Author(s): Kong D, Okamura M, Yoshimi H, Yamori T.
  • Journal Title: Eur J Cancer 45(5) Pages: 857-65
  • Peer Reviewed
• [Journal Article] Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase (2009)
  • Author(s): Kong D, Yaguchi S, Yamori T.
  • Journal Title: Biol Pharm Bull 32(2) Pages: 297-300
  • NAID: 110007042148
  • Peer Reviewed
• [Journal Article] Advances in development of phosphatidylinositol 3-kinase inhibitors (2009)
  • Author(s): Kong D, Yamori T.
  • Journal Title: Curr Med Chem 16(22) Pages: 2839-54
  • Peer Reviewed
• [Journal Article] Identification of Candidate Genes Determining Chemosensitivity to Anticancer Drugs of Gastric Cancer Cell Lines (2009)
  • Author(s): Nakamura T, Nakatsu N, Yoshida Y, Yamazaki K, Dan S, Sadahiro S, Makuuchi H, Yamori T.
  • Journal Title: Biol Pharm Bull 32(11) Pages: 1936-9
  • Peer Reviewed
• [Journal Article] Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5"-epi-Spiruchostatin B, FK228(FR901228)and Preliminary Evaluation of Their Biological Activity (2009)
  • Author(s): Narita K, Kikuchi T, Watanabe K, Takizawa T, Oguchi T, Kudo K, Matsuhara K, Abe H, Yamori T, Yoshida M, Katoh T.
  • Journal Title: Chemistry 15(42) Pages: 11174-86
  • Peer Reviewed
• [Journal Article] Alkyl isothiocyanates suppress epidermal growth factor receptor kinase activity but augment tyrosine kinase activity (2009)
  • Author(s): Nomura T, Uehara Y, Kawajiri H, Ryoyama K, Yamori T, Fuke Y.
  • Journal Title: Cancer Epidemiol 33(3-4) Pages: 288-92
  • Peer Reviewed
• [Journal Article] Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors (2009)
  • Author(s): Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, Yamori T, Tsumoto H, Nakagawa H, Miyata N.
  • Journal Title: J Med Chem 52(9) Pages: 2909-22
  • Peer Reviewed
• [Journal Article] SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells (2009)
  • Author(s): Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, Ichikura T, Yamori T, Nagasaki K, Yoshida M, Matsuoka M, Morishita K, Yuki K, Hanyu A, Miyazawa K, Inazawa J, Miyazono K, Imamura T.
  • Journal Title: J Biol Chem 284(5) Pages: 3334-44
  • Peer Reviewed
• [Journal Article] Proteomic Analysis of Phosphoproteins Sensitive to a Phosphatidylinositol 3-Kinase Inhibitor, ZSTK474, by using SELDI-TOF MS. (2009)
  • Author(s): Akashi T, Yamori T.
  • Journal Title: Proteome Science (in press)
  • Peer Reviewed
• [Journal Article] SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal cancer cells. (2009)
  • Author(s): Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, Ichikura T, Yammori T, Nagasaki K, Yoshida M, Matsuoka M, Morisita K, Yuki K, Hanyu A, Miyazawa K, Inazawa J, Miyazono K, Imamura T.
  • Journal Title: The Journal of biological chemistry 284 Pages: 3334-44
  • Peer Reviewed
• [Journal Article] Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase. (2009)
  • Author(s): Kong D, Yaguchi S, Yamori T.
  • Journal Title: Biological & pharmaceutical bulletin 32 Pages: 297-300
  • NAID: 110007042148
  • Peer Reviewed
• [Journal Article] Anatiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. (2009)
  • Author(s): Kong D, Okamura M, Yoshimi H, Yamori T.
  • Journal Title: EurJ Cancer 45 Pages: 857-65
  • Peer Reviewed
• [Journal Article] Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but GO/G1 arrest. (2009)
  • Author(s): Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T.
  • Journal Title: Biochemical and biophysical research communications 379 Pages: 104-9
  • Peer Reviewed
• [Journal Article] The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity. (2008)
  • Author(s): Wang L, Bai L, Tokunaga D, Watanabe Y, Hasegawa T, Sakai J, Tang W, bai Y, Hirose K, Yamori T, Tomida A, Tsuruo T, Ando M.
  • Journal Title: Journal of Wood Science 54 Pages: 390-401
  • NAID: 10025388074
  • Peer Reviewed
• [Journal Article] A new evaluation method for quantifying PI3K activity by HTRF assay. (2008)
  • Author(s): Sugita H, Dan S, Kong D, Tomida A, Yamoti T.
  • Journal Title: Biochemical and biophysical resarch communicaions 377 Pages: 941-5
  • Peer Reviewed
• [Journal Article] Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. (2008)
  • Author(s): Shiina I, Sano Y, Nakata K, Kikuchi T, Sasaki A, Ikekita M, Nagahara Y, Hasome Y, Yamori T, Yamazaki K.
  • Journal Title: Biochem Pharmacol 75 Pages: 1014-26
  • Peer Reviewed
• [Journal Article] Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria. (2008)
  • Author(s): Saito H, Minamisawa T, Yamori T, Shiba K.
  • Journal Title: Cancer science 99 Pages: 398-406
  • NAID: 10024002827
  • Peer Reviewed
• [Journal Article] Phosphatidylinostiol 3-kinase infibitors : promising drug candidates for cancer therapy. (2008)
  • Author(s): Kong D, Yamori T.
  • Journal Title: Cancer science 99 Pages: 1734-40
  • Peer Reviewed
• [Journal Article] Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines. (2008)
  • Author(s): Kojima N, Hayashi H, Suzuki S, Tominaga H, Maezaki N, Tanaka T, Yamori T.
  • Journal Title: Bioorganic & medicinal chemistry letters 18 Pages: 6451-3
  • Peer Reviewed
• [Journal Article] Synthesis of hybrid acetogenins, alpha, beta-unsaturated-gamma-lactone-free nitrogen-containing heterocyclic analogues, and their cytotoxicity against human cancer cell lines. (2008)
  • Author(s): Kojima N, Fushimi T, Maezaki N, Tanaka T, Yamori T.
  • Journal Title: Bioorganic & medicinal chemistry letters 18 Pages: 1637-41
  • Peer Reviewed
• [Journal Article] Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. (2008)
  • Author(s): Chen CJ, Hsu MH, Huang LJ, Yamori T, Chung JG, Lee FY, Teng CM, Kuo SC.
  • Journal Title: Biochem Pharmacol 75 Pages: 360-8
  • Peer Reviewed
• [Presentation] A New PI3 Kinase Inhibitor ZSTK 474 identified by JFCR39 Cancer Cell Line Panel (2010)
  • Author(s): 矢守隆夫
  • Organizer: 第15回愛知県がん国際シンポジウム
  • Place of Presentation: 名古屋
  • Year and Date: 2010-03-06
• [Presentation] Identification of a novel PI3K inhibitor identified by JFCR39 Cancer Cell Line Panel (2010)
  • Author(s): 矢守隆夫
  • Organizer: Drug and Biologics Japan 2010 conference
  • Place of Presentation: 東京
  • Year and Date: 2010-02-24
• [Presentation] がん分子標的研究の基盤となる Cancer Cell Informatics (2010)
  • Author(s): 矢守隆夫
  • Organizer: システム薬学研究機構/日本バイオインフォマティクス学会シンポジウム
  • Place of Presentation: 東京
  • Year and Date: 2010-01-18
• [Presentation] Correlation between efficacy of PI3K inhibitors and aberration of PI3K3 CA/PTEN in a panel of 39 human cancer cell lines(JFCR39) (2010)
  • Author(s): Dan S, Sugita H, Seki M, Mukai Y, Yamazaki K, Ishikawa Y, Yamori T.
  • Organizer: The 8^<th> AACR/JCA joint conference
  • Place of Presentation: Hawaii, USA
• [Presentation] がん細胞パネルによる化合物の分子標的予測法(CANCER CELL INFORMA TICS):その方法論から分子標的薬開発への応用まで (2009)
  • Author(s): 矢守隆夫
  • Organizer: 平成21星薬科大学オープン・リサーチ・センター・シンポジウム
  • Place of Presentation: 東京
  • Year and Date: 2009-12-05
• [Presentation] A new PI3 kinase inhibitor ZSTK 474 identified by JFCR39 cancer cell lines panel (2009)
  • Author(s): 矢守隆夫
  • Organizer: The 14th Japanese Foundation for Cancer Research International Symposium on Cancer Chemotherapy(ISCC)
  • Place of Presentation: 東京
  • Year and Date: 2009-12-02
• [Presentation] 新規物質の分子標的予測システムの開発と抗がん剤創薬への応用 (2009)
  • Author(s): 矢守隆夫
  • Organizer: 第37回構造活性相関シンポジウム
  • Place of Presentation: 東京
  • Year and Date: 2009-11-12
• [Presentation] PI3K阻害剤ZSTK474とmTOR阻害剤ラパマイシンの併用による抗腫瘍効果増強 (2009)
  • Author(s): 吉見直、岡村睦美、矢守隆夫
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-03
• [Presentation] 新規PI3K阻害剤の開発 (2009)
  • Author(s): 矢守隆夫
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-02
• [Presentation] 肺扁平上皮癌におけるAktと4EBP1のリン酸化 (2009)
  • Author(s): 大場岳彦、中村裕、右田敏郎、奥村栄、矢守隆夫、石川雄一
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-01
• [Presentation] 新規PI3K阻害剤のPI3Kスーパーファミリーに対する阻害プロフィル (2009)
  • Author(s): 孔徳新、矢守隆夫
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-01
• [Presentation] がん細胞運動に対する種々のPI3K阻害剤の効果 (2009)
  • Author(s): 明石哲行、矢守隆夫
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-01
• [Presentation] PI3K阻害剤の変異型PI3Kへの効果 (2009)
  • Author(s): 旦慎吾、山崎佳波、矢守隆夫
  • Organizer: 第68回日本癌学会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-01
• [Presentation] Cancer Cell Informatics による化合物の分子標的予測:その方法論と分子標的薬開発への応用(Prediction of molecular targets of small molecules by Cancer Cell Informatics : Methodology and Application to the development of molecular targeted drugs) (2009)
  • Author(s): 矢守隆夫
  • Organizer: 第26回和漢医薬学会
  • Place of Presentation: 幕張
  • Year and Date: 2009-08-29
• [Presentation] A New PI3 Kinase Inhibitor ZSTK 474 identified by JFCR39 Cancer Cell Lines Panel (2009)
  • Author(s): 矢守隆夫
  • Organizer: PST Medicinal Chemistry Symposium
  • Place of Presentation: Taipei, Taiwan
  • Year and Date: 2009-06-28
• [Presentation] カルボラン含有トリアジン類によるトポイソメラーゼ阻害 (2009)
  • Author(s): 潘鉱承、矢守隆夫、中村啓之
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] クラミドン骨格を有する新規HDAC阻害剤Ky-2の抗腫瘍活性 (2009)
  • Author(s): 前田里子、伊藤昭博、矢守隆夫、西野憲和、吉田稔
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] 分化誘導活性物質NPD723の作用機構解析 (2009)
  • Author(s): 川谷誠、青野晴美、矢守隆夫、長田裕之
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] 新規PI3K阻害剤ZSTK474の血管新生阻害作用 (2009)
  • Author(s): 孔徳新、吉見直、矢守隆夫
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] PI3キナーゼ阻害剤の変異型PI3キナーゼへの効果 (2009)
  • Author(s): 旦慎吾、山崎佳波、矢守隆夫
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] 分子標的創薬とスクリーニング法 (2009)
  • Author(s): 矢守隆夫
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] Telomere Fingerprint Datebase の構築と薬剤反応性研究への応用 (2009)
  • Author(s): 清宮啓之、村松由起子、田原栄俊、矢守隆夫、鶴尾隆
  • Organizer: 第13回日本がん分子標的学会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-25
• [Presentation] A new PI3 kinase inhibitor ZSTK 474 identified by JFCR39 cancer cell lines panel (2009)
  • Author(s): 矢守隆夫
  • Organizer: The 66th KSBMB Annual Meeting
  • Place of Presentation: Coex, Korea
  • Year and Date: 2009-05-12
• [Presentation] Efficary of PI3K inhibitors to PI3K mutants in enzyme and cell levels (2009)
  • Author(s): 旦慎吾、杉田裕宣、山崎佳波、矢守隆夫
  • Organizer: AACR Annual Meeting
  • Place of Presentation: Denver, USA
  • Year and Date: 2009-04-21
• [Presentation] Evaluation of a PI3K inhibitor by an orthotopic brain tumor model (2009)
  • Author(s): Yamori T, Okamura M, Yoshimi H, Kawada M, Fujimaki T.
  • Organizer: AACR Annual Meeting
  • Place of Presentation: Denver, USA
  • Year and Date: 2009-04-21
• [Presentation] Cancer Cell Informaticsによる抗がん分子標的薬創薬研究-新規PI3K阻害剤開発への応用. (2009)
  • Author(s): 矢守隆夫.
  • Organizer: 東邦大学薬学部オープンリサーチセンター第6回老化・老年病研究センター公開セミナー.
  • Place of Presentation: 千葉
  • Year and Date: 2009-03-12
• [Presentation] Enhanced antitumor effect by the combination of a PI3K inhibitor ZST K474 with an mTOR inhibitor rapamycin (2009)
  • Author(s): Yoshimi H, Okamura M, Yamazaki K, Yamori T.
  • Organizer: The 21th EORTC-NCI-AACR symposium
  • Place of Presentation: Boston, USA
• [Presentation] JFCR39 COMPARE system can predict molecular targets of phophatidylinositol 3-kinase inhibitors with high resolution (2009)
  • Author(s): Kong D, Dan S, Yamazaki K, Yamori T.
  • Organizer: The 21th EORTC-NCI-AACR symposium
  • Place of Presentation: Boston, USA
• [Presentation] Efficacy of PI3K inhibitors to cancer cells with PIK3CA mutation or loss of PTEN expression (2009)
  • Author(s): Dan S, Sugita H, Seki M, Mukai Y, Yamazaki K, Ishikawa Y, Yamori T.
  • Organizer: The 21th EORTC-NCI-AACR symposium
  • Place of Presentation: Boston, USA
• [Presentation] Drug discovery of molecular targeted drugs by an information-rich cancer cell line panel JFCR39 (2009)
  • Author(s): 矢守隆夫
  • Organizer: US-Japan International Cancer Systems Biology Meeting
  • Place of Presentation: 横浜
• [Presentation] 新規PI3K阻害剤ZSTK474の血管新生阻害作用 (2009)
  • Author(s): 孔徳新、岡村睦美、吉見直、矢守隆夫
  • Organizer: 第25回日本DDS学会
  • Place of Presentation: 東京
• [Presentation] PI3キナーゼ阻害剤ZSTK474の変異型PI3キナーゼへの効果 (2009)
  • Author(s): 旦慎吾、杉田裕宣、山崎佳波、矢守隆夫
  • Organizer: 第25回日本DDS学会
  • Place of Presentation: 東京
• [Presentation] JFCR39とin silico COMPARE解析によるPI3K阻害剤とAkt阻害剤の比較. (2009)
  • Author(s): 山崎佳波,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] がん細胞による化合物プロフィルの抽出法(Cancer Cell Informatics) : 方法論から分子標的薬開発への応用まで. (2009)
  • Author(s): 矢守隆夫.
  • Organizer: 第2回和漢薬の科学研究シンポジウム.
  • Place of Presentation: 富山
• [Presentation] PI3キナーゼ阻害剤の開発. (2009)
  • Author(s): 矢守隆夫.
  • Organizer: 第7回日本臨床腫瘍学会.
  • Place of Presentation: 名古屋
• [Presentation] カルボラン含有トリアジン類のトポイソメラーゼ阻害活性. (2009)
  • Author(s): 潘鉉承,矢守隆夫,Kang S,中村裕之.
  • Organizer: 日本薬学会第129年会.
  • Place of Presentation: 京都
• [Presentation] 定量的標的プロテオミクスを用いた胃癌及び乳癌細胞株における薬剤耐性に関わる候補トランスポーターの同定. (2009)
  • Author(s): 小渕航,岩瀬怜,大槻純男,上家潤一,矢守隆夫,寺崎哲也.
  • Organizer: 日本薬学会第129年会.
  • Place of Presentation: 京都
• [Presentation] Cancer Cell Informaticsとは-その分子標的治療薬の創薬への応用. (2008)
  • Author(s): 矢守隆夫.
  • Organizer: 創薬薬理フォーラム第16回シンポジウム.
  • Place of Presentation: 東京
  • Year and Date: 2008-09-19
• [Presentation] Cancer Cell Informaticsの開発 -そのがん分子標的薬創薬への応用-. (2008)
  • Author(s): 矢守隆夫.
  • Organizer: 平成20年度神奈川がんセンター臨床研究所・医師の会共催講演会.
  • Place of Presentation: 神奈川
  • Year and Date: 2008-07-22
• [Presentation] Cancer Cell Informaticsとは-そのがん分子標的治療研究への応用. (2008)
  • Author(s): 矢守隆夫
  • Organizer: 重粒子医科学センター第20回研究交流会.
  • Place of Presentation: 東京
  • Year and Date: 2008-05-15
• [Presentation] ZSTK474, a novel PI3K inhibitor, down-regulates CDC25A and induces G1 phase cell cycle arrest in human cancer cells. (2008)
  • Author(s): Dan S, Mukai Y, Yamaguchi S, Yamori T.
  • Organizer: The 100-th Am Assoc Cancer Res (AACR) Annual Meeting.
  • Place of Presentation: San Diego, CA, USA
• [Presentation] Phosphoprotemic screening of biomarkers for assessing response to a PI3K inhibitor by using SELDI-TOF MS. (2008)
  • Author(s): Akashi T, Yaguchi S, Okamura M, Yamori T.
  • Organizer: The100-th Am Assoc Cancer Res (AACR) Annual Meeting.
  • Place of Presentation: San Diego, CA, USA
• [Presentation] ZSTK474 is a specific class I PI3 kinase inhibitor. (2008)
  • Author(s): Kong D, Yaguchi S, Yamori T.
  • Organizer: The100-th Am Assoc Cancer Res (AACR) Annual Meeting.
  • Place of Presentation: San Diego, CA, USA
• [Presentation] Evaluation of antitumor activity of a novel PI3K inhibitor ZSTK474 by various human cancer xenograft models. (2008)
  • Author(s): Yamori T, Okamura M.
  • Organizer: The 20th EORTC-NCI-AACR symposium.
  • Place of Presentation: Geneva, Switzerland
• [Presentation] Anti-anagiogenic activity of a novel PI3K inhibitor, ZSTK474. (2008)
  • Author(s): Kong D, Yoshimi H, Yamori T.
  • Organizer: The 20th EORTC-NCI-AACR symposium.
  • Place of Presentation: Geneva, Switzerland
• [Presentation] Antitumor Effect of a PI3-Kinase Inhibitor ZSTK474 in an Orthotopic Brain Tumor Model. (2008)
  • Author(s): Yamori T, Okamura M, Yoshimi H, Yaguchi S, Kawada M.
  • Organizer: Targeting the PI3-Kinase Pathway in Cancer (AACR Special Conferences).
  • Place of Presentation: Cambridge, Massachusetts, USA
• [Presentation] A New PI3 Kinase Inhibitor ZSTK 474 identified by JFCR39 Cancer Cell Lines Panel. (2008)
  • Author(s): Yamori T.
  • Organizer: 第4回日韓シンポジウム
  • Place of Presentation: 鬼怒川
• [Presentation] 新規PI3キナーゼ阻害剤ZSTK474によるG1アレスト誘導. (2008)
  • Author(s): 旦慎吾,向井由美子,矢口信一,矢守隆夫
  • Organizer: 第12回がん分子標的治療研究会.
  • Place of Presentation: 東京
• [Presentation] CKD阻害因子p15INK4b誘導化合物の探索と新規MEK阻害剤としての固定. (2008)
  • Author(s): 曽根義宏,山口尚之,吉田孝行,掛札れいな,高木浩一,小山真,与五沢真吾,矢守隆夫,酒井敏行.
  • Organizer: 第12回がん分子標的治療研究会.
  • Place of Presentation: 東京
• [Presentation] 新規PI3K阻害剤ZSTK474の特異性. (2008)
  • Author(s): 孔徳新,矢口信一,矢守隆夫.
  • Organizer: 第12回がん分子標的治療研究会.
  • Place of Presentation: 東京
• [Presentation] プロテオミクスによるPI3キナーゼ阻害剤感受性因子の探索. (2008)
  • Author(s): 明石哲行,矢口信一,矢守隆夫.
  • Organizer: 第12回がん分子標的治療研究会.
  • Place of Presentation: 東京
• [Presentation] 含窒素複素環を導入したバンレイシ科アセトゲニン類の合成と癌細胞増殖抑制効果. (2008)
  • Author(s): 小島直人,矢守隆夫.
  • Organizer: 第12回がん分子標的治療研究会.
  • Place of Presentation: 東京
• [Presentation] A New PI3 Kinase Infibitor ZSTK 474 identified by JFCR39 Cancer Cell Pane. (2008)
  • Author(s): Yamori T.
  • Organizer: The 22^<nd> Naito Conference on "Chemical Biology [I].
  • Place of Presentation: 札幌
• [Presentation] Telomere Fingerprint Database : テロメア動態・薬剤反応性研究のための新たなプラットフォーム. (2008)
  • Author(s): 清宮啓之,村松由起子,田原栄俊,上野勝,矢守隆夫,鶴尾隆.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] ヒト卵巣癌細胞の紡錘糸形成におけるTACC3-TOGpのユニークで必須な役割. (2008)
  • Author(s): 八尾良司,矢守隆夫,野田哲生.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] アカデミアにおける分子標的薬検索の試み. (2008)
  • Author(s): 矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] CDK阻害因子p15^<INK4b>誘導化合物の検索と新規MEK阻害剤としての固定. (2008)
  • Author(s): 曽和義広,山口尚之,吉田孝行,掛札れいな,高木浩一,小山真,与五沢真吾,矢守隆夫,酒井敏行.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] 時系列イメージングによる39ヒト癌細胞株の遊走性観察. (2008)
  • Author(s): 明石哲行,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] ヒト肺癌と大腸癌におけるPTEN遺伝子のメチル化解析. (2008)
  • Author(s): 奥井理予,矢守隆夫,山本智理子,中川健,石川雄一.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] HTRFアッセイを用いた定量的なPI3キナーゼ活性測定法の構築. (2008)
  • Author(s): 杉田裕宣,旦真吾,孔徳新,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] 新規PI3K阻害剤ZSTK474のヒト癌24系Xenografを用いた抗腫瘍効果. (2008)
  • Author(s): 岡村睦美,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] 新規PI3K阻害剤ZSTK474の血管新生阻害作用. (2008)
  • Author(s): 孔徳新,吉見直,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] 新規PI3K阻害剤ZSTK474による抗腫瘍メカニズムの解析. (2008)
  • Author(s): 旦真吾,向井由美子,岡村睦美,吉見直,矢口信一,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] インピーダンスによるリアルタイム細胞増殖測定法の開発. (2008)
  • Author(s): 小林雅明,旦慎吾,大橋愛美,矢守隆夫.
  • Organizer: 第67回日本癌学会学術総会.
  • Place of Presentation: 名古屋
• [Presentation] ほ乳類動物細胞におけるTACC3-TOGp依存的な紡錘体形成機構. (2008)
  • Author(s): 八尾良司,矢守隆夫,野田哲生.
  • Organizer: 第31回日本分子生物学会年会 第81回日本生化学大会合同大会.
  • Place of Presentation: 神戸
• [Book] 特集・制がん剤の分子標的スクリーニング成績「化学療法基盤情報支援班」報告-制がん候補物質のスクリーニング成績・第13報- (2010)
  • Author(s): 矢守隆夫、上原至雅、吉田稔、井本正哉、清宮啓之、水上民夫、川田学、長田裕之、松浦正明、深澤秀輔
  • Total Pages: 158
  • Publisher: 癌と化学療法
• [Book] PI3K阻害剤開発の現状 (2009)
  • Author(s): 孔徳新, 矢守隆夫
  • Publisher: 細胞 The CELL
• [Book] 日本がん分子標的治療学会編「がん分子標的治療研究 実践マニュアル」『ヒトがん細胞パネルによる分子標的薬スクリーニング.』 (2009)
  • Author(s): 山崎佳波, 矢守隆夫
  • Total Pages: 329
  • Publisher: 金芳堂
• [Book] 癌領域におけるPI3キナーゼ阻害剤の開発 (2009)
  • Author(s): 矢口信一, 生田目奈知, 矢守隆夫
  • Publisher: Medical Science Digest
• [Book] 山本重夫編「バイオ医薬の開発技術とシーズ」『分子標的薬の基礎および研究動向.』 (2009)
  • Author(s): 矢守隆夫
  • Total Pages: 384
  • Publisher: シーエムシー出版
• [Book] 総論 分子標的薬の動向 (2009)
  • Author(s): 矢守隆夫
  • Publisher: 細胞 The CELL
• [Book] 西條長宏・西尾和人編「がん化学療法・分子標的治療 update」『アカデミアの立場からの新薬開発支援.』 (2009)
  • Author(s): 矢守隆夫
  • Total Pages: 733
  • Publisher: 中外医学社
• [Book] 分子標的薬創薬に有用な Canoer Cell Informatics の構築と応用 (2009)
  • Author(s): 矢守隆夫
  • Publisher: 展望 Promising Vistas in Cancer Research
• [Book] PI3K-Akt-m TOR経路 (2009)
  • Author(s): 矢守隆夫
  • Publisher: カレントテラピー
• [Book] 分子標的薬の基礎および研究動向.(山本重夫編集「バイオ医薬の開発技術とシーズ」) (2009)
  • Author(s): 矢守隆夫.
  • Total Pages: 384
  • Publisher: シーエムシー出版
• [Book] Cancer Cell Informaticsの活用と分子標的薬の探索評価 (2008)
  • Author(s): 矢守隆夫.
  • Publisher: Mebio Oncology
• [Book] がん分子標的研究の基盤となるCancer Cell Informatics (2008)
  • Author(s): 矢守隆夫.
  • Publisher: MEDCHEM NEWS
• [Book] 癌細胞に関する増殖因子の測定法.(日本がん転移学会編集「がん転移研究の実験手法」) (2008)
  • Author(s): 矢守隆夫.
  • Total Pages: 362
  • Publisher: 金芳堂
• [Book] プロテオミクスによる薬剤感受性の検討. (2008)
  • Author(s): 明石哲行,矢守隆夫.
  • Publisher: 腫瘍内科
• [Book] Cancer Cell Informaticsと分子標的薬剤.(鶴尾隆編集「がんの分子標的治療」) (2008)
  • Author(s): 旦慎吾,矢守隆夫.
  • Total Pages: 441
  • Publisher: 南山堂
• [Book] PI3Kの新しい阻害剤. (2008)
  • Author(s): 孔徳新,矢守隆夫.
  • Publisher: 生体の科学